NEW YORK (GenomeWeb) – Contract research organization Nanosyn today announced a multiyear research service agreement to provide its microfluidics screening and profiling capabilities to Forma Therapeutics.
Nanosyn will provide to Forma its lab-on-a-chip biology services, which comprises more than 500 mobility shift assays. Forma will have access to Nanosyn's screening and profiling services and fragment-based screening drug discovery platform.
Nanosyn will also develop novel assays in support of Forma's epigenetic and protein homeostasis programs, including screening against Forma's and Nanosyn's proprietary chemical libraries, while Forma will support biological and medicinal chemistry activities at Nanosyn for Forma's hit-to-lead and lead optimization programs, Nanosyn said.
Financial and other terms of the deal were not disclosed.
Nanosyn is based in Santa Clara, Calif., and provides assay development, screening and profiling services, integrated drug discovery and development services, and other capabilities.